Overshadowing as prevention of anticipatory nausea and vomiting
Completed
- Conditions
- Pediatric oncologyCancer
- Registration Number
- ISRCTN30242271
- Lead Sponsor
- niversity of Kiel (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. New diagnosis
2. German speaking
3. Age from 4 years
4. Receiving 3 chemotherapy cycles
5. Intervals of 7 days in-between the single chemotherapy cycles
Exclusion Criteria
1. CNS or gastrointestinal tract cancer
2. Mental restrictions
3. Recurrent cancer
4. Prior radiotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method anticipatory nausea and vomiting (via patient administered discomfort logs)
- Secondary Outcome Measures
Name Time Method 1. Post-treatment nausea and vomiting (via patient administered discomfort logs)<br>2. Quality of life (via patient administered KINDL-R questionnaire), state-anxiety (via patient administered KAT-II, form P / STAI) and adherence (via ratings by medical personnel)<br>3. Relation between prevalence of post-treatment and anticipatory nausea and vomiting<br>4. Applicability of the overshadowing treatment in the hospital?s daily routine